Aktuelle smitsomme sygdomme
Søgeord (covid-19) valgt.
35 emner vises.
Martin Šmíd, Tamara Barusová, Jiří Jarkovský, Ondřej Májek, Tomáš Pavlík, Lenka Přibylová, Josefína Weinerová, Milan Zajíček and Jan Trnka
Eurosurveillance latest updates, 30.08.2024
Tilføjet 30.08.2024
BackgroundCOVID-19 remains a major infectious disease with substantial implications for individual and public health including the risk of a post-infection syndrome, long COVID. The continuous changes in dominant variants of SARS-CoV-2 necessitate a careful study of the effect of preventative strategies. AimWe aimed to estimate the effectiveness of post-vaccination, post-infection and hybrid immunity against severe cases requiring oxygen support caused by infections with SARS-CoV-2 variants BA1/2 and BA4/5+, and against long COVID in the infected population and their changes over time. MethodsWe used a Cox regression analysis with time-varying covariates and calendar time and logistic regression applied to national-level data from Czechia from December 2021 until August 2023. ResultsRecently boosted vaccination, post-infection and hybrid immunity provide significant protection against a severe course of COVID-19, while unboosted vaccination more than 10 months ago has a negligible protective effect. The post-vaccination immunity against the BA1/2 or BA4/5+ variants, especially based on the original vaccine types, appears to wane rapidly compared with post-infection and hybrid immunity. Once infected, however, previous immunity plays only a small protective role against long COVID. ConclusionVaccination remains an effective preventative measure against a severe course of COVID-19 but its effectiveness wanes over time thus highlighting the importance of booster doses. Once infected, vaccines may have a small protective effect against the development of long COVID.
Læs mereMedscape Infectious Diseases, 28.08.2024
Tilføjet 28.08.2024
The program\'s end will leave the Canadian province without a valuable tool for monitoring infectious disease. Medscape Medical News
Læs mereMedscape Infectious Diseases, 23.08.2024
Tilføjet 23.08.2024
A large study shows higher rates of depression and mental illness up to a year after COVID-19, especially severe cases of the infection, in unvaccinated adults. Medscape Medical News
Læs mereMedscape Infectious Diseases, 23.08.2024
Tilføjet 23.08.2024
COVID-19 vaccination was not associated with increased risk for multiple sclerosis relapse, except in those with high MS activity. Medscape Medical News
Læs mereMattijs S Lambooij, Joyce Pijpers, Jan van de Kassteele, Mirjam P Fransen, Susan JM Hahné, Niek Hof, Floor M Kroese, Hester de Melker, Mart van Dijk, Ellen Uiters and Marijn de Bruin
Eurosurveillance latest updates, 23.08.2024
Tilføjet 23.08.2024
BackgroundVaccine uptake differs between social groups. Mobile vaccination units (MV-units) were deployed in the Netherlands by municipal health services in neighbourhoods with low uptake of COVID-19 vaccines. AimWe aimed to evaluate the impact of MV-units on vaccine uptake in neighbourhoods with low vaccine uptake. MethodsWe used the Dutch national-level registry of COVID-19 vaccinations (CIMS) and MV-unit deployment registrations containing observations in 253 neighbourhoods where MV-units were deployed and 890 contiguous neighbourhoods (total observations: 88,543 neighbourhood-days). A negative binomial regression with neighbourhood-specific temporal effects using splines was used to study the effect. ResultsDuring deployment, the increase in daily vaccination rate in targeted neighbourhoods ranged from a factor 2.0 (95% confidence interval (CI): 1.8–2.2) in urbanised neighbourhoods to 14.5 (95% CI: 11.6–18.0) in rural neighbourhoods. The effects were larger in neighbourhoods with more voters for the Dutch conservative Reformed Christian party but smaller in neighbourhoods with a higher proportion of people with non-western migration backgrounds. The absolute increase in uptake over the complete intervention period ranged from 0.22 percentage points (95% CI: 0.18–0.26) in the most urbanised neighbourhoods to 0.33 percentage point (95% CI: 0.28–0.37) in rural neighbourhoods. ConclusionDeployment of MV-units increased daily vaccination rate, particularly in rural neighbourhoods, with longer travel distance to permanent vaccination locations. This public health intervention shows promise to reduce geographic and social health inequalities, but more proactive and long-term deployment is required to identify its potential to substantially contribute to overall vaccination rates at country level.
Læs mereLea Gur-Arie, Michal Stein, Hanna Sefty, Ilana S Fratty, Ital Nemet, Limor Kliker, Nofar Atari, Neta S Zuckerman, Alina Rosenberg, Heftziba Ivgi, Orit Golan-Shany, Nadav Sorek, Orna Schwartz-Harari, Michal Bromberg, Lital Keinan-Boker, Michal Mandelboim, Aharona Glatman-Freedman and on behalf of the Israeli Respiratory Viruses Hospital Laboratory Network (IRVHLN)
Eurosurveillance latest updates, 9.08.2024
Tilføjet 9.08.2024
BackgroundA new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic. AimWe aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework. MethodsData of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework. ResultsThe new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives. ConclusionThe new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.
Læs mereStatens Serum Institut, 8.08.2024
Tilføjet 8.08.2024
Ny undersøgelse fra WHO/Europa bekræfter den livsreddende effekt af covid-19-vacciner. Statens Serum Institut (SSI) har bidraget til undersøgelsen, som er relevant i en tid med flere årlige smittebølger.
Læs mereMedscape Infectious Diseases, 8.08.2024
Tilføjet 8.08.2024
Administering anti–IL-6 therapy in later pregnancy may be safe for women who would benefit from it, showed a study that evaluated its safety in critically ill pregnant women with COVID-19. Medscape Medical News
Læs mereDani Cohen, Orit Treygerman, Shifra Ken-Dror, Orli Sagi, Merav Strauss, Miriam Parizade, Sophy Goren, Analía V Ezernitchi, Assaf Rokney, Lital Keinan-Boker and Ravit Bassal
Eurosurveillance latest updates, 2.08.2024
Tilføjet 2.08.2024
BackgroundShigella is a leading cause of moderate-to-severe diarrhoea worldwide and diarrhoeal deaths in children in low- and-middle-income countries. AimWe investigated trends and characteristics of shigellosis and antimicrobial resistance of Shigella sonnei in Israel. MethodsWe analysed data generated by the Sentinel Laboratory-Based Surveillance Network for Enteric Pathogens that systematically collects data on detection of Shigella at sentinel laboratories, along with the characterisation of the isolates at the Shigella National Reference Laboratory. Trends in the shigellosis incidence were assessed using Joinpoint regression and interrupted time-series analyses. ResultsThe average incidence of culture-confirmed shigellosis in Israel declined from 114 per 100,000 population (95% confidence interval (CI): 112–115) 1998–2004 to 80 per 100,000 population (95% CI: 79–82) 2005–2011. This rate remained stable 2012–2019, being 18–32 times higher than that reported from the United States or European high-income countries. After decreasing to its lowest values during the COVID-19 pandemic years (19/100,000 in 2020 and 5/100,000 in 2021), the incidence of culture-confirmed shigellosis increased to 39 per 100,000 population in 2022. Shigella sonnei is the most common serogroup, responsible for a cyclic occurrence of propagated epidemics, and the proportion of Shigella flexneri has decreased. Simultaneous resistance of S. sonnei to ceftriaxone, ampicillin and sulphamethoxazole-trimethoprim increased from 8.5% (34/402) in 2020 to 92.0% (801/876) in 2022. ConclusionsThese findings reinforce the need for continuous laboratory-based surveillance and inform the primary and secondary prevention strategies for shigellosis in Israel and other endemic high-income countries or communities.
Læs mereCarla Rodrigues, Valérie Bouchez, Anaïs Soares, Sabine Trombert-Paolantoni, Fatima Aït El Belghiti, Jérémie F Cohen, Nathalie Armatys, Annie Landier, Thomas Blanchot, Marie Hervo, REMICOQ study group, Julie Toubiana and Sylvain Brisse
Eurosurveillance latest updates, 2.08.2024
Tilføjet 2.08.2024
As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.
Læs mereMedscape Infectious Diseases, 30.07.2024
Tilføjet 30.07.2024
COVID-19 vaccine maker BioNTech\'s cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial,... Reuters Health Information
Læs mereECDC
ECDC COVID-19 updates, 29.07.2024
Tilføjet 29.07.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mereMaria Siopi, Panagiota-Christina Georgiou, Paschalis Paranos, Maria-Ioanna Beredaki, Aikaterini Tarpatzi, Eleni Kalogeropoulou, Sofia Damianidou, Alexandra Vasilakopoulou, Polyxeni Karakosta, Spyros Pournaras and Joseph Meletiadis
Eurosurveillance latest updates, 20.07.2024
Tilføjet 20.07.2024
BackgroundThe COVID-19 pandemic and the emergence of Candida auris have changed the epidemiological landscape of candidaemia worldwide. AimWe compared the epidemiological trends of candidaemia in a Greek tertiary academic hospital before (2009–2018) and during the early COVID-19 (2020–2021) and late COVID-19/early post-pandemic (2022–2023) era. MethodsIncidence rates, species distribution, antifungal susceptibility profile and antifungal consumption were recorded, and one-way ANOVA or Fisher’s exact test performed. Species were identified by MALDI-ToF MS, and in vitro susceptibility determined with CLSI M27-Ed4 for C. auris and the EUCAST-E.DEF 7.3.2 for other Candida spp. ResultsIn total, 370 candidaemia episodes were recorded during the COVID-19 pandemic. Infection incidence (2.0 episodes/10,000 hospital bed days before, 3.9 during the early and 5.1 during the late COVID-19 era, p
Læs mereLouise Marron, Alberto Mateo-Urdiales, Joan O’Donnell, Eve Robinson and Lisa Domegan
Eurosurveillance latest updates, 12.07.2024
Tilføjet 12.07.2024
BackgroundAs Ireland prepared for an autumn 2023 COVID-19 vaccination booster campaign, there was concern that vaccine fatigue would affect uptake, which has been abating. AimThis study aimed to quantify the direct impact of the COVID-19 vaccination programme in Ireland on averted COVID-19-related outcomes including symptomatic presentations to primary care/community testing centres, emergency department (ED) presentations, hospitalisations, intensive care unit (ICU) admissions and deaths, in individuals aged ≥ 50 years, during Omicron dominance. MethodsWe conducted a retrospective observational COVID-19 vaccine impact study in December 2021–March 2023 in Ireland. We used national data on notified outcomes and vaccine coverage, as well as vaccine effectiveness (VE) estimates, sourced from the World Health Organization’s live systematic review of VE, to estimate the count and prevented fraction of outcomes in ≥ 50-year-olds averted by the COVID-19 vaccination programme in this age group. ResultsThe COVID-19 vaccination programme averted 48,551 symptomatic COVID-19 presentations to primary care/community testing centres (36% of cases expected in the absence of vaccination), 9,517 ED presentations (53% of expected), 102,160 hospitalisations (81% of expected), 3,303 ICU admissions (89% of expected) and 15,985 deaths (87% of expected). ConclusionsWhen Omicron predominated, the COVID-19 vaccination programme averted symptomatic and severe COVID-19 cases, including deaths due to COVID-19. In line with other international vaccine impact studies, these findings emphasise the benefits of COVID-19 vaccination for population health and the healthcare system and are relevant for informing COVID-19 booster vaccination programmes, pandemic preparedness and communicating the reason for and importance of COVID-19 vaccination in Ireland and internationally.
Læs mereLaila Toro, Henriette de Valk, Laura Zanetti, Caroline Huot, Arnaud Tarantola, Nelly Fournet, Laurent Moulin, Ali Atoui, Benoît Gassilloud, Damien Mouly and Frédéric Jourdain
Eurosurveillance latest updates, 12.07.2024
Tilføjet 12.07.2024
BackgroundWastewater surveillance is an effective approach to monitor population health, as exemplified by its role throughout the COVID-19 pandemic. AimThis study explores the possibility of extending wastewater surveillance to the Paris 2024 Olympic and Paralympic Games, focusing on identifying priority pathogen targets that are relevant and feasible to monitor in wastewater for these events. MethodsA list of 60 pathogens of interest for general public health surveillance for the Games was compiled. Each pathogen was evaluated against three inclusion criteria: (A) analytical feasibility; (B) relevance, i.e. with regards to the specificities of the event and the characteristics of the pathogen; and (C) added value to inform public health decision-making. Analytical feasibility was assessed through evidence from peer-reviewed publications demonstrating the detectability of pathogens in sewage, refining the initial list to 25 pathogens. Criteria B and C were evaluated via expert opinion using the Delphi method. The panel consisting of some 30 experts proposed five additional pathogens meeting criterion A, totalling 30 pathogens assessed throughout the three-round iterative questionnaire. Pathogens failing to reach 70% group consensus threshold underwent further deliberation by a subgroup of experts. ResultsSix priority targets suitable for wastewater surveillance during the Games were successfully identified: poliovirus, influenza A virus, influenza B virus, mpox virus, SARS-CoV-2 and measles virus. ConclusionThis study introduced a model framework for identifying context-specific wastewater surveillance targets for a mass gathering. Successful implementation of a wastewater surveillance plan for Paris 2024 could incentivise similar monitoring efforts for other mass gatherings globally.
Læs mereMaaike C Swets, Annabel Niessen, Emilie P Buddingh, Ann CTM Vossen, Karin Ellen Veldkamp, Irene K Veldhuijzen, Mark GJ de Boer and Geert H Groeneveld
Eurosurveillance latest updates, 5.07.2024
Tilføjet 5.07.2024
BackgroundEffective pandemic preparedness requires robust severe acute respiratory infection (SARI) surveillance. However, identifying SARI patients based on symptoms is time-consuming. Using the number of reverse transcription (RT)-PCR tests or contact and droplet precaution labels as a proxy for SARI could accurately reflect the epidemiology of patients presenting with SARI. AimWe aimed to compare the number of RT-PCR tests, contact and droplet precaution labels and SARI-related International Classification of Disease (ICD)-10 codes and evaluate their use as surveillance indicators. MethodsPatients from all age groups hospitalised at Leiden University Medical Center between 1 January 2017 up to and including 30 April 2023 were eligible for inclusion. We used a clinical data collection tool to extract data from electronic medical records. For each surveillance indicator, we plotted the absolute count for each week, the incidence proportion per week and the correlation between the three surveillance indicators. ResultsWe included 117,404 hospital admissions. The three surveillance indicators generally followed a similar pattern before and during the COVID-19 pandemic. The correlation was highest between contact and droplet precaution labels and ICD-10 diagnostic codes (Pearson correlation coefficient: 0.84). There was a strong increase in the number of RT-PCR tests after the start of the COVID-19 pandemic. DiscussionAll three surveillance indicators have advantages and disadvantages. ICD-10 diagnostic codes are suitable but are subject to reporting delays. Contact and droplet precaution labels are a feasible option for automated SARI surveillance, since these reflect trends in SARI incidence and may be available real-time.
Læs mereMedscape Infectious Diseases, 1.07.2024
Tilføjet 1.07.2024
AstraZeneca said on Monday that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug,... Reuters Health Information
Læs mereMedscape Infectious Diseases, 28.06.2024
Tilføjet 28.06.2024
The U.S. Centers for Disease Control and Prevention has recommended that individuals aged six months and older should be given an updated COVID-19 vaccine for the 2024-25... Reuters Health Information
Læs mereBianca Schulte, Enrico Richter, Antonia Büning, Maximilian Baum, Annika Breuer, Jasmin Zorn, Julia König, Melanie Geiger, Monika Eschbach-Bludau, Johanna Heuser, Dominik Zölzer, Marek Korencak, Ronja Hollstein, Eva Beins, Dorian Emmert, Souhaib Aldabbagh, Anna Maria Eis-Hübinger and Hendrik Streeck
Eurosurveillance latest updates, 28.06.2024
Tilføjet 28.06.2024
BackgroundSince its emergence in December 2019, over 700 million people worldwide have been infected with SARS-CoV-2 up to May 2024. While early rollout of mRNA vaccines against COVID-19 has saved many lives, there was increasing immune escape of new virus variants. Longitudinal monitoring of population-wide SARS-CoV-2 antibody responses from regular sample collection irrespective of symptoms provides representative data on infection and seroconversion/seroreversion rates. AimTo examine adaptive and cellular immune responses of a German SARS-CoV-2 outbreak cohort through several waves of infection with different virus variants. MethodsUtilising a 31-month longitudinal seroepidemiological study (n = 1,446; mean age: 50 years, range: 2–103) initiated during the first SARS-CoV-2 superspreading event (February 2020) in Heinsberg, Germany, we analysed acute infection, seroconversion and virus neutralisation at five follow-up visits between October 2020 and November 2022; cellular and cross-protective immunity against SARS-CoV-2 Omicron variants were also examined. ResultsSARS-CoV-2 spike (S)-specific IgAs decreased shortly after infection, while IgGs remained stable. Both increased significantly after vaccination. We predict an 18-month half-life of S IgGs upon infection. Nucleocapsid (N)-specific responses declined over 12 months post-infection but increased (p
Læs mereMedscape Infectious Diseases, 25.06.2024
Tilføjet 25.06.2024
The COVID-19 pandemic has been associated with reported declines in cancer screenings. Now a new study suggested these decreases extended through 2022 for cervical cancer screening in particular. Medscape Medical News
Læs mereMinke R Holwerda, Christina E Hoeve, Anne J Huiberts, Gerco den Hartog, Hester E de Melker, Susan van den Hof and Mirjam J Knol
Eurosurveillance latest updates, 22.06.2024
Tilføjet 22.06.2024
BackgroundNon-severe adverse events (AE) including pain at injection site or fever are common after COVID-19 vaccination. AimTo describe determinants of AE after COVID-19 vaccination and investigate the association between AE and pre- and post-vaccination antibody concentrations. MethodsParticipants of an ongoing prospective cohort study (VASCO) completed a questionnaire on AE within 2 months after vaccination and provided 6 monthly serum samples during May 2021–November 2022. Logistic regression analyses were performed to investigate AE determinants after mRNA vaccination, including pre-vaccination Ig antibody concentrations against the SARS-CoV-2 spike protein receptor binding domain. Multivariable linear regression was performed in SARS-CoV-2-naive participants to assess the association between AE and log-transformed antibody concentrations 3–8 weeks after mRNA vaccination. ResultsWe received 47,947 completed AE questionnaires by 28,032 participants. In 42% and 34% of questionnaires, injection site and systemic AE were reported, respectively. In 2.2% of questionnaires, participants sought medical attention. AE were reported more frequently by women, younger participants (
Læs mereECDC
ECDC COVID-19 updates, 21.06.2024
Tilføjet 21.06.2024
This After-Action Review (AAR) investigates the use of evidence in Norway’s advice-making process about school continuity in secondary (13–15 years old) and upper secondary schools (16–18 years old) during the COVID-19 pandemic.
Læs mereMedscape Infectious Diseases, 19.06.2024
Tilføjet 19.06.2024
Is a slow recovery from COVID-19 the lingering effects of a bad infection or the start of a new syndrome? Medscape
Læs mereMedscape Infectious Diseases, 13.06.2024
Tilføjet 13.06.2024
Moderna said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared... Reuters Health Information
Læs mereStatens Serum Institut, 11.06.2024
Tilføjet 11.06.2024
Efter et dyk i forbruget under covid-19-pandemien bruger vi igen mere antibiotika i Danmark. Stigningen ses både hos de yngste og ældste borgere, viser nye tal fra DANMAP-programmet.
Læs mereOlga Frank, David Acitores Balboa, Maria Novatchkova, Ezgi Özkan, Marcus Martin Strobl, Ramesh Yelagandula, Tanino Guiseppe Albanese, Lukas Endler, Fabian Amman, Vera Felsenstein, Milanka Gavrilovic, Melanie Acosta, Timothej Patocka, Alexander Vogt, Ido Tamir, Julia Klikovits, Alexander Zoufaly, Tamara Seitz, Manuela Födinger, Andreas Bergthaler, Alexander Indra, Daniela Schmid, Peter Klimek, Alexander Stark, Franz Allerberger, Bernhard Benka, Katharina Reich, Luisa Cochella and Ulrich Elling
Eurosurveillance latest updates, 7.06.2024
Tilføjet 7.06.2024
BackgroundThe COVID-19 pandemic was largely driven by genetic mutations of SARS-CoV-2, leading in some instances to enhanced infectiousness of the virus or its capacity to evade the host immune system. To closely monitor SARS-CoV-2 evolution and resulting variants at genomic-level, an innovative pipeline termed SARSeq was developed in Austria. AimWe discuss technical aspects of the SARSeq pipeline, describe its performance and present noteworthy results it enabled during the pandemic in Austria. MethodsThe SARSeq pipeline was set up as a collaboration between private and public clinical diagnostic laboratories, a public health agency, and an academic institution. Representative SARS-CoV-2 positive specimens from each of the nine Austrian provinces were obtained from SARS-CoV-2 testing laboratories and processed centrally in an academic setting for S-gene sequencing and analysis. ResultsSARS-CoV-2 sequences from up to 2,880 cases weekly resulted in 222,784 characterised case samples in January 2021–March 2023. Consequently, Austria delivered the fourth densest genomic surveillance worldwide in a very resource-efficient manner. While most SARS-CoV-2 variants during the study showed comparable kinetic behaviour in all of Austria, some, like Beta, had a more focused spread. This highlighted multifaceted aspects of local population-level acquired immunity. The nationwide surveillance system enabled reliable nowcasting. Measured early growth kinetics of variants were predictive of later incidence peaks. ConclusionWith low automation, labour, and cost requirements, SARSeq is adaptable to monitor other pathogens and advantageous even for resource-limited countries. This multiplexed genomic surveillance system has potential as a rapid response tool for future emerging threats.
Læs mereMedscape Infectious Diseases, 6.06.2024
Tilføjet 6.06.2024
Advisers to the U.S. Food and Drug Administration on Wednesday unanimously voted in favor of recommending that COVID-19 vaccines for 2024-25 should target a strain within... Reuters Health Information
Læs mereMedscape Infectious Diseases, 6.06.2024
Tilføjet 6.06.2024
Former top U.S. infectious disease expert Dr. Anthony Fauci strongly denied suppressing the theory that COVID-19 originated from a lab leak in China, telling lawmakers he... Reuters Health Information
Læs mereMedscape Infectious Diseases, 4.06.2024
Tilføjet 4.06.2024
For the first time, an mRNA vaccine has been approved for an indication other than COVID-19. The vaccine will join a couple other immunizations currently on the market for respiratory syncytial virus. Medscape Medical News
Læs mereMarlène Guillet, Ariane Bas, Marjorie Lacoste, Céline Ricard, Catherine Visse, Valérie Barlet, Lucile Malard, Sophie Le Cam, Pascal Morel, Xavier de Lamballerie, Syria Laperche and Pierre Gallian
Eurosurveillance latest updates, 26.05.2024
Tilføjet 26.05.2024
In France, blood donations are tested in pools of 96 samples for parvovirus B19 (B19V) DNA to discard plasma for fractionation when it contains high viral loads. Between January 2015 and March 2024, B19V-positive donations decreased during the COVID-19 pandemic, followed by a strong rebound in 2023 and unusually high circulation during winter 2023/24 (ca 10 times higher December 2023–March 2024 vs the pre-pandemic period). Variations over time are probably related to measures implemented to limit SARS-CoV-2 spread.
Læs mereMarlène Guillet, Ariane Bas, Marjorie Lacoste, Céline Ricard, Catherine Visse, Valérie Barlet, Lucile Malard, Sophie Le Cam, Pascal Morel, Xavier de Lamballerie, Syria Laperche and Pierre Gallian
Eurosurveillance latest updates, 24.05.2024
Tilføjet 24.05.2024
In France, blood donations are tested in pools of 96 samples for parvovirus B19 (B19V) DNA to discard plasma for fractionation when it contains high viral loads. Between January 2015 and March 2024, B19V-positive donations decreased during the COVID-19 pandemic, followed by a strong rebound in 2023 and unusually high circulation during winter 2023/24 (ca 10 times higher December 2023–March 2024 vs the pre-pandemic period). Variations over time are probably related to measures implemented to limit SARS-CoV-2 spread.
Læs mereFranziska Hommes, Achim Dörre, Susanne C Behnke, Klaus Stark and Mirko Faber
Eurosurveillance latest updates, 17.05.2024
Tilføjet 17.05.2024
BackgroundGiardia duodenalis is a major cause of gastroenteritis globally, and is the most common food- and waterborne parasitic infection in Europe. AimTo describe the epidemiology of reported acute giardiasis cases in Germany and compare demographic and clinical characteristics between imported and autochthonous cases. MethodsWe conducted a descriptive analysis of giardiasis cases that fulfilled the national case definition and were reported between January 2002 and December 2021. We defined an imported case as having at least one place of exposure abroad in the 3–25 days before symptom onset. We analysed case numbers and incidence by age, sex, month reported and geographic region, both overall and stratified by autochthonous and imported cases. ResultsFrom 2002 to 2021, 72,318 giardiasis cases were reported in Germany, corresponding to a mean annual incidence of 4.4 per 100,000 population. Annual incidence gradually decreased since 2013, declining sharply during the COVID-19 pandemic in 2020–21. Of 69,345 cases reported between 2002 and 2019, 35% were imported. Incidence of autochthonous cases (overall yearly mean: 3.1/100,000) was highest in males and young children (
Læs mereWei Cai, Sophie Köndgen, Kristin Tolksdorf, Ralf Dürrwald, Barbara Biere, Walter Haas, Thorsten Wolff, Silke Buda and Janine Reiche
Eurosurveillance latest updates, 17.05.2024
Tilføjet 17.05.2024
Statens Serum Institut, 16.05.2024
Tilføjet 16.05.2024
Nyt studie viser, at efterårets covid-19-vaccine er mindre effektiv over for de nye covid-varianter, der har domineret smittebilledet den forgangne vinter. Men vaccinen har stadig en væsentlig effekt.
Læs mereMedscape Infectious Diseases, 16.05.2024
Tilføjet 16.05.2024
CDC experts share what clinicians should know about COVID-19 prevention in immunocompromised patients. CDC Expert Commentary
Læs mere